You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDabigatran etexilate
Accession NumberDB06695
TypeSmall Molecule
GroupsApproved
DescriptionDabigatran etexilate is an oral prodrug that is metabolized by a serum esterase to dabigatran. It is a synthetic, competitive and reversible direct thrombin inhibitor. Inhibition of thrombin disrupts the coagulation cascade and inhibits the formation of clots. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients who have undergone total hip or knee replacement surgery, or to prevent stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary. FDA approved on October 19, 2010.
Structure
Thumb
Synonyms
Dabigatran
Ethyl 3-[[[4-[[[(hexyloxyl)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino] propanoate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PradaxaCapsule75 mgOralBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule150 mgOralBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule110 mg/1OralBoehringer Ingelheim Pharmaceuticals Inc.2015-11-23Not applicableUs
PradaxaCapsule150 mgOralBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule110 mgOralBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule150 mg/1OralA S Medication Solutions2010-10-26Not applicableUs
PradaxaCapsule75 mgOralBoehringer Ingelheim (Canada) Ltd Ltee2008-07-03Not applicableCanada
PradaxaCapsule150 mgOralBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule75 mgOralBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule75 mgOralBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule150 mgOralBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule150 mg/1OralBoehringer Ingelheim Pharmaceuticals Inc.2010-10-26Not applicableUs
PradaxaCapsule110 mgOralBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule110 mgOralBoehringer Ingelheim (Canada) Ltd Ltee2008-07-03Not applicableCanada
PradaxaCapsule110 mgOralBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule110 mgOralBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule75 mgOralBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule150 mgOralBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule75 mg/1OralBoehringer Ingelheim Pharmaceuticals Inc.2011-08-08Not applicableUs
PradaxaCapsule110 mgOralBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule150 mgOralBoehringer Ingelheim (Canada) Ltd Ltee2010-11-03Not applicableCanada
PradaxaCapsule110 mgOralBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule150 mgOralBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule75 mgOralBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule150 mgOralBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
PradaxaCapsule150 mg/1OralRebel Distributors Corp2010-10-26Not applicableUs
PradaxaCapsule110 mgOralBoehringer Ingelheim International Gmb H2008-03-18Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PradaxBoehringer Ingelheim
RendixNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Dabigatran etexilate mesilate
872728-81-9
Thumb
  • InChI Key: XETBXHPXHHOLOE-UHFFFAOYSA-N
  • Monoisotopic Mass: 723.305032141
  • Average Mass: 723.839
DBSALT000035
Categories
UNII2E18WX195X
CAS number211915-06-9
WeightAverage: 627.7332
Monoisotopic: 627.316917457
Chemical FormulaC34H41N7O5
InChI KeyKSGXQBZTULBEEQ-UHFFFAOYSA-N
InChI
InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)
IUPAC Name
ethyl 3-(1-{2-[({4-[amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-(pyridin-2-yl)formamido)propanoate
SMILES
CCCCCCOC(=O)N=C(N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=CC=CC=N3)N2C)C=C1
Pharmacology
IndicationDabigatran is indicated for the prevention of venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery (based on RE-NOVATE, RE-MODEL, and RE-MOBILIZE trials). In 2010, it was approved in the US and Canada for prevention of stroke and systemic embolism in patients with atrial fibrillation (approval based on the RE-LY trial). Contraindications: severe renal impairment (CrCL < 30 ml/min); haemorrhagic manifestations, bleeding diathesis or spontaneous or pharmacologic impairment of haemostasis; lesions at risk of clinically significant bleeding (e.g. extensive cerebral infarction (haemorrhagic or ischemic) in the last 6 months, active peptic ulcer disease); concomitant treatment with P-glycoprotein inhibitors (e.g. oral ketoconazole, verapamil); and those with known hypersensitivity to dabigatran, dabigatran etexilate or any ingredient used in the formulation or component of the container. As of December 2012, dabigatran is contraindicated in patients with mechanical prosthetic heart valves.
Structured Indications
PharmacodynamicsDabigatran directly inhibits thrombin in a concentration-dependent, reversible, specific, and competitive manner which results in a prolongation of aPTT (partial thromboplastin time), ECT (Ecarin clotting time), and TT (thrombin time). It may increase INR but this laboratory parameter is relatively insensitive to the activity of dabigatran.
Mechanism of actionDabigatran etexilate is an inactive pro-drug that is converted to dabigatran, the active form, by esterase-catalyzed hydrolysis in the plasma and liver. Dabigatran, the main active principle in plasma, is a rapid-acting competitive and reversible direct inhibitor of thrombin. Thrombin, a serine protease, is responsible for the conversion of fibrinogen to fibrin in the coagulation cascade. Inhibition of thrombin consequently prevents thrombus development. Dabigatran inhibits free thrombin, fibrin-bound thrombin and thrombin-induced platelet aggregation.
TargetKindPharmacological actionActionsOrganismUniProt ID
ProthrombinProteinyes
inhibitor
HumanP00734 details
Related Articles
AbsorptionPeak plasma concentrations were achieved in 6 hours in post surgical patients. In healthy patients, maximum concentrations were achieved in 0.5 to 2 hours. The absolute bioavailability of dabigatran in the body after administration of dabigatran etexilate was 6.5%. Food does not affect the bioavailability of dabigatran etexilate, but it delays the time to peak plasma concentrations by 2 hours. Oral bioavailability may increase by up to 75% when pellets are taken out of the hydroxypropylmethylcellulose (HPMC) capsule. Therefore, capsules should not be opened and pellets taken alone. Furthermore, although absorption of dabigatran etexilate is independent of gastrointestinal acidity, coadministration of pantoprazole (proton pump inhibitor) may reduce the bioavailability of dabigatran. Despite this finding, dose adjustment is not required.
Volume of distribution

Moderate tissue distribution with a Vd of 60-70L.
Accumulation factor, twice daily dosing = 2

Protein bindingRelatively low binding (34-35%) to plasma proteins.
Metabolism

CYP450 enzymes are not involved in the metabolism of dabigatran thus is not expected to interact with drugs metabolized by CYP isoenzymes. Dabigatran is typically metabolised by esterases and microsomal carboxylesterases. Pharmacologically active acylglucoronides are formed via conjugation. Four positional isomers, 1-O, 2-O, 3-O, and 4-O, acylglucuronides exist, each accounting for less than 10% of total plasma dabagatran.

Route of eliminationMainly excreted in urine (85%). Fecal excretion accounts for 6% of the orally administered dose. Dabigatran is primarily eliminated unchanged via the kidneys at a rate of 100 ml/min corresponding to the glomerular filtration rate.
Half life12-14 hours in healthy volunteers. 14-17 hours in patients treated for prevention of venous thromboembolism following hip- or knee-replacement surgery.
ClearanceNot Available
ToxicityThe most common adverse reactions include dyspepsia or gastritis-like symptoms. The approximate lethal dose (LD50) in rats and mice was observed at single oral doses of > 2000 mg/kg. Oral doses of 600 mg/kg did not induce any toxicologically meaningful changes in dogs and Rhesus monkeys. Dabigatran was well-tolerated in rats and Rhesus monkeys during repeat-dose toxicity studies. No evidence of mutagenic potential.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Dabigatran etexilate.Approved, Investigational
AbciximabDabigatran etexilate may increase the anticoagulant activities of Abciximab.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Dabigatran etexilate.Approved
AcenocoumarolDabigatran etexilate may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Acetaminophen.Approved
AcetovanilloneAcetovanillone may increase the anticoagulant activities of Dabigatran etexilate.Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Dabigatran etexilate.Approved
AfatinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Afatinib.Approved
AlbendazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Alectinib.Approved
AlfentanilThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Alfentanil.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Dabigatran etexilate.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Allylestrenol.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Dabigatran etexilate.Approved, Illicit, Investigational
AlprostadilAlprostadil may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Dabigatran etexilate.Approved
AltrenogestThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Altrenogest.Vet Approved
Aluminum hydroxideThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminum hydroxide.Approved
Aluminum phosphateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminum phosphate.Approved
ALX-0081ALX-0081 may increase the anticoagulant activities of Dabigatran etexilate.Investigational
AmantadineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Amantadine.Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Dabigatran etexilate.Experimental
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Dabigatran etexilate.Illicit, Withdrawn
Aminohippuric acidThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Aminohippuric acid.Approved
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Dabigatran etexilate.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
AmiodaroneThe serum concentration of Dabigatran etexilate can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Amitriptyline.Approved
AmlodipineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Amlodipine.Approved
AmprenavirThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Amsacrine.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Dabigatran etexilate.Approved
AncrodDabigatran etexilate may increase the anticoagulant activities of Ancrod.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Dabigatran etexilate.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Dabigatran etexilate.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Dabigatran etexilate.Approved
Antithrombin III humanDabigatran etexilate may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Dabigatran etexilate.Approved
ApremilastApremilast may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
AprotininThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinDabigatran etexilate may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanDabigatran etexilate may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Dabigatran etexilate.Investigational
AstemizoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Atazanavir.Approved, Investigational
AtenololThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Atenolol.Approved
AtorvastatinThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Atorvastatin.Approved
AzapropazoneAzapropazone may increase the anticoagulant activities of Dabigatran etexilate.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Dabigatran etexilate.Approved
AzithromycinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Azithromycin.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Dabigatran etexilate.Experimental
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
BecaplerminDabigatran etexilate may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Dabigatran etexilate.Approved
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Dabigatran etexilate.Withdrawn
BenzocaineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Benzocaine.Approved
BepridilThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bepridil.Approved, Withdrawn
BeraprostBeraprost may increase the anticoagulant activities of Dabigatran etexilate.Investigational
Betulinic AcidBetulinic Acid may increase the anticoagulant activities of Dabigatran etexilate.Investigational
BiperidenThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Biperiden.Approved
Bismuth SubcitrateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Bismuth Subcitrate.Approved
BivalirudinDabigatran etexilate may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Boceprevir.Approved
BosutinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bosutinib.Approved
BromfenacBromfenac may increase the anticoagulant activities of Dabigatran etexilate.Approved
BromocriptineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the anticoagulant activities of Dabigatran etexilate.Investigational
BuprenorphineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Buspirone.Approved, Investigational
ButylphthalideButylphthalide may increase the anticoagulant activities of Dabigatran etexilate.Investigational
CabazitaxelThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cabazitaxel.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Dabigatran etexilate.Approved
CaffeineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Caffeine.Approved
Calcium carbonateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Calcium carbonate.Approved
CanagliflozinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Canagliflozin.Approved
CandesartanThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Candesartan.Approved
CangrelorCangrelor may increase the anticoagulant activities of Dabigatran etexilate.Approved
CaptoprilThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Captopril.Approved
CarbamazepineThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Caspofungin.Approved
CastanospermineCastanospermine may increase the anticoagulant activities of Dabigatran etexilate.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
CertoparinDabigatran etexilate may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chloroquine.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Dabigatran etexilate.Withdrawn
ChlorpromazineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cholesterol.Experimental
Cholic AcidThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cilazapril.Approved
CilostazolCilostazol may increase the anticoagulant activities of Dabigatran etexilate.Approved
CimetidineThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Dabigatran etexilate.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Citalopram.Approved
Citric AcidDabigatran etexilate may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe serum concentration of Dabigatran etexilate can be increased when it is combined with Clarithromycin.Approved
ClofazimineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Clomipramine.Approved, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Dabigatran etexilate.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Dabigatran etexilate.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cobicistat.Approved
ColchicineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Colchicine.Approved
ColforsinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Colforsin.Experimental
CollagenaseThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Collagenase.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Dabigatran etexilate.Approved
CrizotinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Crizotinib.Approved
CurcuminCurcumin may increase the anticoagulant activities of Dabigatran etexilate.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Dabigatran etexilate.Approved
CyclophosphamideThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Dabigatran etexilate.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may increase the anticoagulant activities of Dabigatran etexilate.Investigational
DaclatasvirThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Daclatasvir.Approved
DactinomycinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dactinomycin.Approved
DalteparinDabigatran etexilate may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidDabigatran etexilate may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DasatinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Dabigatran etexilate.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Deoxycholic Acid.Approved
dersalazinedersalazine may increase the anticoagulant activities of Dabigatran etexilate.Investigational
DesipramineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Desipramine.Approved
DesirudinDabigatran etexilate may increase the anticoagulant activities of Desirudin.Approved
DesloratadineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Desloratadine.Approved, Investigational
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Dabigatran etexilate.Investigational
DesogestrelThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Desogestrel.Approved
DexamethasoneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextranDabigatran etexilate may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Dabigatran etexilate may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Dabigatran etexilate may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Dabigatran etexilate may increase the anticoagulant activities of Dextran 75.Approved
DextromethorphanThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dextromethorphan.Approved
DiclofenacThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Diclofenac.Approved, Vet Approved
DicoumarolDabigatran etexilate may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Dabigatran etexilate.Approved
DienogestThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Dabigatran etexilate.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Dabigatran etexilate.Approved
DigoxinThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dihydroergotamine.Approved
DiltiazemThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Diltiazem.Approved
DipyridamoleDipyridamole may increase the anticoagulant activities of Dabigatran etexilate.Approved
DitazoleDitazole may increase the anticoagulant activities of Dabigatran etexilate.Approved, Withdrawn
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Dabigatran etexilate.Approved
DoxazosinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Doxazosin.Approved
DoxepinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Doxepin.Approved
DoxorubicinThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Dabigatran etexilate can be increased when it is combined with Dronedarone.Approved
DrospirenoneThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Drospirenone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Dabigatran etexilate.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Dabigatran etexilate.Investigational
DydrogesteroneThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Dydrogesterone.Approved, Withdrawn
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Dabigatran etexilate.Approved
E6201E6201 may increase the anticoagulant activities of Dabigatran etexilate.Investigational
EbselenEbselen may increase the anticoagulant activities of Dabigatran etexilate.Investigational
Edetic AcidDabigatran etexilate may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanDabigatran etexilate may increase the anticoagulant activities of Edoxaban.Approved
ElbasvirThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Elbasvir.Approved
EnalaprilThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Enalapril.Approved, Vet Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Dabigatran etexilate.Approved, Investigational
EnoxaparinDabigatran etexilate may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Enzalutamide.Approved
EpinastineEpinastine may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Dabigatran etexilate.Approved
eplivanserineeplivanserine may increase the anticoagulant activities of Dabigatran etexilate.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Dabigatran etexilate.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Dabigatran etexilate.Approved
ErgonovineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ergonovine.Approved
ErgotamineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ergotamine.Approved
ErythromycinThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Erythromycin.Approved, Vet Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Dabigatran etexilate.Investigational
EsomeprazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Esomeprazole resulting in a loss in efficacy.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Dabigatran etexilate.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Estramustine.Approved
EstriolThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Estriol.Approved, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Dabigatran etexilate.Approved
EstroneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Estrone.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Dabigatran etexilate.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Dabigatran etexilate.Approved
Ethyl biscoumacetateDabigatran etexilate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Ethynodiol diacetate.Approved
EtodolacEtodolac may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Dabigatran etexilate.Approved
EtonogestrelThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoposideThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Etoposide.Approved
EtoricoxibEtoricoxib may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
EtravirineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Etravirine.Approved
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Dabigatran etexilate.Approved
exisulindexisulind may increase the anticoagulant activities of Dabigatran etexilate.Investigational
FelodipineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Felodipine.Approved, Investigational
FenbufenFenbufen may increase the anticoagulant activities of Dabigatran etexilate.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved
FentanylThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fexofenadine.Approved
FibrinolysinFibrinolysin may increase the anticoagulant activities of Dabigatran etexilate.Approved
FidaxomicinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fidaxomicin.Approved
FloctafenineFloctafenine may increase the anticoagulant activities of Dabigatran etexilate.Approved, Withdrawn
FluconazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluconazole.Approved
FluindioneDabigatran etexilate may increase the anticoagulant activities of Fluindione.Investigational
FlunixinFlunixin may increase the anticoagulant activities of Dabigatran etexilate.Vet Approved
FluoxetineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluphenazine.Approved
FlurazepamThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Flurazepam.Approved, Illicit
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
FluvoxamineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluvoxamine.Approved, Investigational
FondaparinuxDabigatran etexilate may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumDabigatran etexilate may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexateDabigatran etexilate may increase the anticoagulant activities of Gabexate.Investigational
GarlicThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Garlic.Approved
GefitinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Gefitinib.Approved, Investigational
GenisteinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Genistein.Investigational
GestodeneThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Gestodene.Approved
GestrinoneThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Gestrinone.Approved
GlyburideThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Glyburide.Approved
GlycerolThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Glycerol.Experimental
Gramicidin DThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Gramicidin D.Approved
GrepafloxacinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Haloperidol.Approved
HeminHemin may increase the anticoagulant activities of Dabigatran etexilate.Approved
HeparinDabigatran etexilate may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Dabigatran etexilate.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Dabigatran etexilate.Investigational
HirulogDabigatran etexilate may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004HMPL-004 may increase the anticoagulant activities of Dabigatran etexilate.Investigational
HydrocortisoneThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Hydrocortisone.Approved, Vet Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Dabigatran etexilate.Approved
IbudilastIbudilast may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Dabigatran etexilate.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Dabigatran etexilate.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Dabigatran etexilate.Approved, Nutraceutical
IdelalisibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Idelalisib.Approved
idraparinuxDabigatran etexilate may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Dabigatran etexilate.Approved, Withdrawn
IloprostIloprost may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
ImatinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Imatinib.Approved
ImipramineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Imipramine.Approved
IndinavirThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Indinavir.Approved
IndobufenIndobufen may increase the anticoagulant activities of Dabigatran etexilate.Investigational
IndomethacinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Indomethacin.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Dabigatran etexilate.Withdrawn
IsavuconazoniumThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Isavuconazonium.Approved, Investigational
IsoxicamIsoxicam may increase the anticoagulant activities of Dabigatran etexilate.Withdrawn
ItraconazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ivacaftor.Approved
IvermectinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ivermectin.Approved, Vet Approved
Kct 0809Kct 0809 may increase the anticoagulant activities of Dabigatran etexilate.Investigational
KebuzoneKebuzone may increase the anticoagulant activities of Dabigatran etexilate.Experimental
KetamineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ketamine.Approved, Vet Approved
KetanserinKetanserin may increase the anticoagulant activities of Dabigatran etexilate.Investigational
KetoconazoleThe serum concentration of Dabigatran etexilate can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoconazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Dabigatran etexilate.Approved
LansoprazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lapatinib.Approved, Investigational
LeflunomideLeflunomide may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
LepirudinDabigatran etexilate may increase the anticoagulant activities of Lepirudin.Approved
LevofloxacinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Levofloxacin.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LevothyroxineThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lidocaine.Approved, Vet Approved
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Dabigatran etexilate.Approved
LiothyronineThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lisinopril.Approved, Investigational
LisofyllineLisofylline may increase the anticoagulant activities of Dabigatran etexilate.Investigational
LomitapideThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lomitapide.Approved
LoperamideThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Loperamide.Approved
LopinavirThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lopinavir.Approved
LoratadineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Loratadine.Approved
LornoxicamLornoxicam may increase the anticoagulant activities of Dabigatran etexilate.Approved
LosartanThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Losartan.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Dabigatran etexilate.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved
LumacaftorThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
LynestrenolThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Lynestrenol.Investigational
MagaldrateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magaldrate.Withdrawn
Magnesium carbonateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium carbonate.Approved
Magnesium hydroxideThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium hydroxide.Approved
Magnesium oxideThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium oxide.Approved
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Dabigatran etexilate.Approved
Magnesium TrisilicateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium Trisilicate.Approved
MaprotilineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Maprotiline.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Dabigatran etexilate.Approved
MebendazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Mebendazole.Approved, Vet Approved
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
MefloquineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Mefloquine.Approved
Megestrol acetateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Megestrol acetate.Approved, Vet Approved
MeloxicamMeloxicam may increase the anticoagulant activities of Dabigatran etexilate.Approved, Vet Approved
MeprobamateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Meprobamate.Approved, Illicit
MesalazineMesalazine may increase the anticoagulant activities of Dabigatran etexilate.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Dabigatran etexilate.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Dabigatran etexilate.Withdrawn
MethadoneThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Methadone.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Dabigatran etexilate.Experimental
MetoprololThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Mibefradil.Withdrawn
MiconazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Mifepristone.Approved, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Dabigatran etexilate.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Dabigatran etexilate.Approved
MitomycinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Mitomycin.Approved
MitoxantroneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineMizoribine may increase the anticoagulant activities of Dabigatran etexilate.Investigational
MorphineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Morphine.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Dabigatran etexilate.Approved
NadroparinDabigatran etexilate may increase the anticoagulant activities of Nadroparin.Approved
NafamostatDabigatran etexilate may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineNaftifine may increase the anticoagulant activities of Dabigatran etexilate.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Dabigatran etexilate.Investigational
NaltrexoneThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Naltrexone.Approved, Investigational, Vet Approved
NaproxenNaproxen may increase the anticoagulant activities of Dabigatran etexilate.Approved, Vet Approved
NaringeninThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Naringenin.Experimental
NCX 4016NCX 4016 may increase the anticoagulant activities of Dabigatran etexilate.Investigational
NefazodoneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Neostigmine.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Dabigatran etexilate.Approved
NicardipineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nicardipine.Approved
NifedipineThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Nifedipine.Approved
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
NilotinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the anticoagulant activities of Dabigatran etexilate.Approved, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Nintedanib.Approved
NisoldipineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nisoldipine.Approved
NitrazepamThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nitrazepam.Approved
NitrendipineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nitrendipine.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Dabigatran etexilate.Investigational
NomegestrolThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Norethisterone.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Dabigatran etexilate.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Obinutuzumab.Approved
OlopatadineOlopatadine may increase the anticoagulant activities of Dabigatran etexilate.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Dabigatran etexilate.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Omacetaxine mepesuccinate.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Dabigatran etexilate.Approved
OmeprazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Omeprazole.Approved, Investigational, Vet Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Dabigatran etexilate.Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Dabigatran etexilate.Vet Approved
OtamixabanDabigatran etexilate may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Dabigatran etexilate.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Dabigatran etexilate.Withdrawn
P-NitrophenolThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Paclitaxel.Approved, Vet Approved
Palmitic AcidThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pantoprazole.Approved
ParecoxibParecoxib may increase the anticoagulant activities of Dabigatran etexilate.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Dabigatran etexilate.Approved
ParoxetineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Paroxetine.Approved, Investigational
Pentosan PolysulfateDabigatran etexilate may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
PerindoprilThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Pethidine.Approved
PhenindioneDabigatran etexilate may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Phenobarbital.Approved
PhenprocoumonDabigatran etexilate may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Dabigatran etexilate.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Dabigatran etexilate.Approved
PirfenidonePirfenidone may increase the anticoagulant activities of Dabigatran etexilate.Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
PlasminPlasmin may increase the anticoagulant activities of Dabigatran etexilate.Investigational
Platelet Activating FactorThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Platelet Activating Factor.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Dabigatran etexilate.Approved
PonatinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ponatinib.Approved
PosaconazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Posaconazole.Approved, Investigational, Vet Approved
PrasugrelPrasugrel may increase the anticoagulant activities of Dabigatran etexilate.Approved
PravastatinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pravastatin.Approved
PrazosinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Prazosin.Approved
PrednisoneThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Prednisone.Approved, Vet Approved
ProbenecidThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Probenecid.Approved
ProgesteroneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromestrienePromestriene may decrease the anticoagulant activities of Dabigatran etexilate.Investigational
PromethazineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Promethazine.Approved
PropacetamolPropacetamol may increase the anticoagulant activities of Dabigatran etexilate.Approved
PropafenoneThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Propafenone.Approved
PropranololThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Propranolol.Approved, Investigational
Protein CDabigatran etexilate may increase the anticoagulant activities of Protein C.Approved
Protein S humanDabigatran etexilate may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeDabigatran etexilate may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Protriptyline.Approved
PTC299PTC299 may increase the anticoagulant activities of Dabigatran etexilate.Investigational
QuercetinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Quercetin.Experimental
QuinacrineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Quinacrine.Approved
QuinestrolQuinestrol may decrease the anticoagulant activities of Dabigatran etexilate.Approved
QuinidineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Quinine.Approved
RabeprazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Rabeprazole resulting in a loss in efficacy.Approved, Investigational
RamatrobanRamatroban may increase the anticoagulant activities of Dabigatran etexilate.Investigational
RanitidineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ranitidine.Approved
RanolazineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Regorafenib.Approved
ReserpineThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Reserpine.Approved
ResveratrolResveratrol may increase the anticoagulant activities of Dabigatran etexilate.Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Dabigatran etexilate.Approved
ReviparinDabigatran etexilate may increase the anticoagulant activities of Reviparin.Approved
RidogrelRidogrel may increase the anticoagulant activities of Dabigatran etexilate.Approved
RifampicinThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Rifampicin.Approved
RilpivirineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Rilpivirine.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Dabigatran etexilate.Approved
RitonavirThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanDabigatran etexilate may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Dabigatran etexilate.Investigational, Withdrawn
RolapitantThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Rolapitant.Approved
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Dabigatran etexilate.Approved
S EquolS Equol may decrease the anticoagulant activities of Dabigatran etexilate.Investigational
SalicylamideSalicylamide may increase the anticoagulant activities of Dabigatran etexilate.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Dabigatran etexilate.Approved
SaquinavirThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Saquinavir.Approved, Investigational
SCH-530348SCH-530348 may increase the anticoagulant activities of Dabigatran etexilate.Investigational
ScopolamineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Scopolamine.Approved
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Dabigatran etexilate.Investigational
SelegilineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Selegiline.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the anticoagulant activities of Dabigatran etexilate.Approved
SeratrodastSeratrodast may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
SertralineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sertraline.Approved
SevofluraneSevoflurane may increase the anticoagulant activities of Dabigatran etexilate.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Dabigatran etexilate.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Dabigatran etexilate.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Dabigatran etexilate.Approved
SirolimusThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Sirolimus.Approved, Investigational
SorafenibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Spironolactone.Approved
SRT501SRT501 may increase the anticoagulant activities of Dabigatran etexilate.Investigational
St. John's WortThe metabolism of Dabigatran etexilate can be increased when combined with St. John&#39;s Wort.Nutraceutical
StaurosporineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Staurosporine.Experimental
StreptokinaseStreptokinase may increase the anticoagulant activities of Dabigatran etexilate.Approved
StreptozocinThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Streptozocin.Approved
SugammadexSugammadex may increase the anticoagulant activities of Dabigatran etexilate.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Dabigatran etexilate.Approved
SulfinpyrazoneSulfinpyrazone may increase the anticoagulant activities of Dabigatran etexilate.Approved
SulindacSulindac may increase the anticoagulant activities of Dabigatran etexilate.Approved
SulodexideDabigatran etexilate may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SumatriptanThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Dabigatran etexilate.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dabigatran etexilate.Approved
TacrineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Tacrine.Withdrawn
TacrolimusThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Tacrolimus.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Dabigatran etexilate.Approved, Investigational
TAK-390MRThe serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with TAK-390MR resulting in a loss in efficacy.Investigational
TamoxifenThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Taurocholic Acid.Experimental
TelmisartanThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Telmisartan.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Temsirolimus.Approved
TenecteplaseTenecteplase may increase the anticoagulant activities of Dabigatran etexilate.Approved
TenoxicamTenoxicam may increase the anticoagulant activities of Dabigatran etexilate.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Dabigatran etexilate.Vet Approved
TerazosinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Terazosin.Approved
TerfenadineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Terfenadine.Withdrawn
TeriflunomideTeriflunomide may increase the anticoagulant activities of Dabigatran etexilate.Approved
TesmilifeneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Testosterone.Approved, Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Dabigatran etexilate.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Dabigatran etexilate.Approved
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
TiboloneTibolone may increase the anticoagulant activities of Dabigatran etexilate.Approved
TicagrelorTicagrelor may increase the anticoagulant activities of Dabigatran etexilate.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Dabigatran etexilate.Approved
TinoridineTinoridine may increase the anticoagulant activities of Dabigatran etexilate.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Dabigatran etexilate.Approved
TipranavirThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Tipranavir.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Dabigatran etexilate.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
TolmetinTolmetin may increase the anticoagulant activities of Dabigatran etexilate.Approved
TolvaptanThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Tolvaptan.Approved
TositumomabThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Tositumomab.Approved
TranilastTranilast may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Dabigatran etexilate.Approved
TrazodoneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Dabigatran etexilate.Approved
TrifluoperazineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Trifluoperazine.Approved
TriflupromazineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Triflupromazine.Approved, Vet Approved
TriflusalTriflusal may increase the anticoagulant activities of Dabigatran etexilate.Approved
TrimethoprimThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Trimipramine.Approved
Trisalicylate-cholineTrisalicylate-choline may increase the anticoagulant activities of Dabigatran etexilate.Approved
TroleandomycinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Troleandomycin.Approved
UrokinaseUrokinase may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Dabigatran etexilate.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Dabigatran etexilate.Approved, Investigational
VenlafaxineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Venlafaxine.Approved
VerapamilThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Verapamil.Approved
VinblastineThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Vinorelbine.Approved, Investigational
Vitamin EVitamin E may increase the anticoagulant activities of Dabigatran etexilate.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Dabigatran etexilate.Approved
WarfarinDabigatran etexilate may increase the anticoagulant activities of Warfarin.Approved
XimelagatranDabigatran etexilate may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Dabigatran etexilate may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved
ZeranolZeranol may decrease the anticoagulant activities of Dabigatran etexilate.Vet Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Dabigatran etexilate.Approved
ZileutonZileuton may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Zimelidine.Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Dabigatran etexilate.Withdrawn
Food Interactions
  • St. John's Wort
References
Synthesis Reference

Christian Filser, Wolfgang Dersch, Rainer Hamm, Arndt Hausherr, Gunter Koch, Ulrich Scholz, Georg Zerban, “METHOD FOR PRODUCING AN INTERMEDIATE PRODUCT OF DABIGATRAN ETEXILATE.” U.S. Patent US20110118471, issued May 19, 2011.

US20110118471
General References
  1. Bauer KA: New oral anticoagulants in development: potential for improved safety profiles. Rev Neurol Dis. 2010;7(1):1-8. [PubMed:20410856 ]
  2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. [PubMed:19717844 ]
  3. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI: Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost. 2009 Jan;101(1):77-85. [PubMed:19132192 ]
  4. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA: Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan;24(1):1-9. doi: 10.1016/j.arth.2008.01.132. Epub 2008 Apr 14. [PubMed:18534438 ]
  5. Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kalebo P, Reilly P: A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005 Jan;3(1):103-11. [PubMed:15634273 ]
  6. Di Nisio M, Middeldorp S, Buller HR: Direct thrombin inhibitors. N Engl J Med. 2005 Sep 8;353(10):1028-40. [PubMed:16148288 ]
  7. Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, Rathgen K, Svard R: Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005 May;45(5):555-63. [PubMed:15831779 ]
  8. Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L: Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007 Nov 1;100(9):1419-26. Epub 2007 Aug 17. [PubMed:17950801 ]
  9. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Buller HR: Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007 Nov;5(11):2178-85. [PubMed:17764540 ]
  10. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR: Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007 Sep 15;370(9591):949-56. [PubMed:17869635 ]
  11. Scaglione F: New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013 Feb;52(2):69-82. doi: 10.1007/s40262-012-0030-9. [PubMed:23292752 ]
External Links
ATC CodesB01AE07
AHFS Codes
  • 20:12.04.12
PDB EntriesNot Available
FDA labelDownload (431 KB)
MSDSDownload (99.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.942
Blood Brain Barrier+0.8673
Caco-2 permeable-0.7014
P-glycoprotein substrateSubstrate0.7412
P-glycoprotein inhibitor IInhibitor0.7539
P-glycoprotein inhibitor IIInhibitor0.8443
Renal organic cation transporterNon-inhibitor0.701
CYP450 2C9 substrateNon-substrate0.858
CYP450 2D6 substrateNon-substrate0.837
CYP450 3A4 substrateSubstrate0.6154
CYP450 1A2 substrateNon-inhibitor0.6906
CYP450 2C9 inhibitorNon-inhibitor0.5102
CYP450 2D6 inhibitorNon-inhibitor0.8417
CYP450 2C19 inhibitorInhibitor0.5157
CYP450 3A4 inhibitorInhibitor0.781
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5789
Ames testNon AMES toxic0.6292
CarcinogenicityNon-carcinogens0.8065
BiodegradationNot ready biodegradable0.9931
Rat acute toxicity2.7093 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9047
hERG inhibition (predictor II)Inhibitor0.6181
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
CapsuleOral110 mg/1
CapsuleOral110 mg
CapsuleOral150 mg
CapsuleOral150 mg/1
CapsuleOral75 mg
CapsuleOral75 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6087380 No1998-02-182018-02-18Us
US7866474 No2007-08-312027-08-31Us
US7932273 No2005-09-072025-09-07Us
US9034822 No2011-01-202031-01-20Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point180 +/- 3 (DSC: 10 K min^-1 heating rate)Not Available
water solubility1.8mg/ml, partly soluble MSDS
logP3.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00466 mg/mLALOGPS
logP5.17ALOGPS
logP4.59ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)17.89ChemAxon
pKa (Strongest Basic)3.87ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area154.03 Å2ChemAxon
Rotatable Bond Count17ChemAxon
Refractivity176.43 m3·mol-1ChemAxon
Polarizability71.11 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzimidazoles
Sub ClassNot Available
Direct ParentBenzimidazoles
Alternative Parents
Substituents
  • Benzimidazole
  • Benzamide
  • Phenylalkylamine
  • Substituted aniline
  • Benzoyl
  • Aralkylamine
  • Secondary aliphatic/aromatic amine
  • Aniline
  • Aminopyridine
  • Imidolactam
  • Benzenoid
  • Pyridine
  • N-substituted imidazole
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Tertiary amine
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboximidamide
  • Secondary amine
  • Carboxylic acid derivative
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Thrombospondin receptor activity
Specific Function:
Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.
Gene Name:
F2
Uniprot ID:
P00734
Molecular Weight:
70036.295 Da
References
  1. Squizzato A, Dentali F, Steidl L, Ageno W: New direct thrombin inhibitors. Intern Emerg Med. 2009 Dec;4(6):479-84. doi: 10.1007/s11739-009-0314-8. Epub 2009 Sep 15. [PubMed:19756950 ]
  2. Liesenfeld KH, Schafer HG, Troconiz IF, Tillmann C, Eriksson BI, Stangier J: Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol. 2006 Nov;62(5):527-37. [PubMed:17061960 ]
  3. Karthikeyan G, Eikelboom JW, Hirsh J: Dabigatran: ready for prime time? Pol Arch Med Wewn. 2010 Apr;120(4):137-42. [PubMed:20424539 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Triglyceride lipase activity
Specific Function:
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester. Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine. Catalyzes the transesterification of cocaine to form cocaethylene. Displays fatty acid ethyl ester synthase activity,...
Gene Name:
CES1
Uniprot ID:
P23141
Molecular Weight:
62520.62 Da
References
  1. Hu ZY, Parker RB, Herring VL, Laizure SC: Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013 Feb;405(5):1695-704. doi: 10.1007/s00216-012-6576-4. Epub 2012 Dec 14. [PubMed:23239178 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Methylumbelliferyl-acetate deacetylase activity
Specific Function:
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Shows high catalytic efficiency for hydrolysis of cocaine, 4-methylumbelliferyl acetate, heroin and 6-monoacetylmorphine.
Gene Name:
CES2
Uniprot ID:
O00748
Molecular Weight:
61806.41 Da
References
  1. Hu ZY, Parker RB, Herring VL, Laizure SC: Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013 Feb;405(5):1695-704. doi: 10.1007/s00216-012-6576-4. Epub 2012 Dec 14. [PubMed:23239178 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Ebner T, Wagner K, Wienen W: Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75. doi: 10.1124/dmd.110.033696. Epub 2010 Jun 15. [PubMed:20551237 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Ebner T, Wagner K, Wienen W: Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75. doi: 10.1124/dmd.110.033696. Epub 2010 Jun 15. [PubMed:20551237 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme displays activity toward several classes of xenobiotic substrates, including simple phenolic compounds, 7-hydroxylated coumarins, flavonoids, anthraquinones, and certain drugs and their hydroxylated metabolites. It also catalyzes the glucuronidatio...
Gene Name:
UGT2B15
Uniprot ID:
P54855
Molecular Weight:
61035.815 Da
References
  1. Ebner T, Wagner K, Wienen W: Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75. doi: 10.1124/dmd.110.033696. Epub 2010 Jun 15. [PubMed:20551237 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Nadph dehydrogenase (quinone) activity
Specific Function:
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis.
Gene Name:
NQO2
Uniprot ID:
P16083
Molecular Weight:
25918.4 Da
References
  1. Michaelis S, Marais A, Schrey AK, Graebner OY, Schaudt C, Sefkow M, Kroll F, Dreger M, Glinski M, Koester H, Metternich R, Fischer JJ: Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2). J Med Chem. 2012 Apr 26;55(8):3934-44. doi: 10.1021/jm3001339. Epub 2012 Apr 17. [PubMed:22494098 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Galanis T, Thomson L, Palladino M, Merli GJ: New oral anticoagulants. J Thromb Thrombolysis. 2011 Apr;31(3):310-20. doi: 10.1007/s11239-011-0559-8. [PubMed:21327511 ]
  2. Scaglione F: New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013 Feb;52(2):69-82. doi: 10.1007/s40262-012-0030-9. [PubMed:23292752 ]
Comments
comments powered by Disqus
Drug created on May 03, 2010 12:25 / Updated on December 08, 2016 11:11